Targeting nanotherapy a promising treatment for abdominal aortic aneurysms
The multifunctional, targeting nanotherapy shows potential in the treatment of abdominal aortic aneurysms (AAA), a recent study suggests.
“The underlying design principles enable the development of a broad range of nanomedicines for targeted therapy of other vascular disease,” the authors said.
A rapamycin-loaded responsive nanotherapy was formulated successfully based on a facile and translational method. This medicine could release drug molecules upon the trigger by high levels of reactive oxygen species (ROS).
Calcification was significantly prevented while ROS-mediated oxidative stress and apoptosis were attenuated by the nanotherapy in cells linked to the development of AAAs.
Passively targeting aneurysms and releasing drug molecules in response to the inflammatory microenvironment allowed the intravenously injected ROS-responsive nanotherapy to more effectively prevent aneurysm expansion in AAA rats than a nonresponsive control nanotherapy.
There was further improvement in the aneurysmal targeting capability and therapeutic effects of a ROS-responsive nanotherapy with a mean diameter of 190 nm after decoration with a peptide ligand cRGDfK and macrophage cell membrane. The nanotherapy was also safe according to a preliminary safety test.
This study sought to develop a nanotherapy that can target aneurysms and release drug molecules in response to the inflammatory microenvironment. The nanotherapy was developed using a ROS-responsive nanoparticle and a candidate drug rapamycin, in combination with a peptide ligand for integrin and biomimetic cloaking with macrophage cell membrane. Its efficacy was shown by in vitro and in vivo studies.
“AAA is a leading cause of mortality and morbidity in the elderly,” the authors said. “Currently, there remain no effective drugs that can prevent the growth of aneurysms and delay aneurysm rupture in the clinical setting.”